Results for intensifikatur translation from Maltese to English

intensifikatur tal-immaġni
image intensifier

intensifikatur farmakokinetiku u mediċini oħra użati flimkien miegħu
pharmacokinetic enhancer and concomitant medications

għalhekk, darunavir għandu jintuża biss flimkien ma’ intensifikatur farmakokinetiku (ara sezzjoni 5.2).
therefore, darunavir must only be used in combination with a pharmacokinetic enhancer (see section 5.2).

il-profil ta’ interazzjoni ta’ darunavir jiddependi fuq jekk jintużax ritonavir jew cobicistat bħala intensifikatur farmakokinetiku.
the interaction profile of darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.

prezista għandu jintuża biss flimkien ma 100 mg ritonavir li jservi ta ’ intensifikatur farmakokinetiku (ara sezzjoni 5. 2).
prezista should only be used in combination with 100 mg of ritonavir as a pharmacokinetic enhancer (see section 5.2).

prezista għandu dejjem jingħata mill- ħalq flimkien ma 100 mg ritonavir li jservi ta ’ intensifikatur farmakokinetiku u flimkien ma ’ prodotti mediċinali antiretrovirali oħra.
prezista must always be given orally with 100 mg ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.

prezista għandu dejjem jingħata mill-ħalq flimkien ma doża baxxa ta’ ritonavir li jservi ta’ intensifikatur farmakokinetiku u flimkien ma’ prodotti mediċinali antiretrovirali oħra.
prezista must always be given orally with low dose ritonavir as a pharmacokinetic enhancer and in combination with other antiretroviral medicinal products.

cobicistat bħala intensifikatur farmakokinetiku ta’ darunavir għandu, għalhekk, ma jinbediex f’pazjenti bi tneħħija tal-kreatinina inqas minn 70 ml/min jekk kwalunkwe waħda mis-sustanzi mogħtija miegħu tkun teħtieġ aġġustament fid-doża abbażi ta’ tneħħija tal-kreatinina: eż. emtricitabine, lamivudine, tenofovir disoproxil fumarate jew adefovir dipovoxil.
cobicistat as a pharmacokinetic enhancer of darunavir should, therefore, not be initiated in patients with creatine clearance less than 70 ml/min if any co-administered agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine, lamivudine, tenofovir disoproxil fumarate or adefovir dipovoxil.